These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
46. Fecal calprotectin levels predict the clinical course in patients with new onset of ulcerative colitis. Lasson A; Simrén M; Stotzer PO; Isaksson S; Ohman L; Strid H Inflamm Bowel Dis; 2013 Mar; 19(3):576-81. PubMed ID: 23377170 [TBL] [Abstract][Full Text] [Related]
47. Faecal calprotectin level for assessing endoscopic activity and predicting future clinical course in patients with moderately active ulcerative colitis undergoing granulomonocytapheresis: a prospective cohort study. Shimoyama T; Yamamoto T; Umegae S; Matsumoto K BMC Gastroenterol; 2018 Aug; 18(1):120. PubMed ID: 30068300 [TBL] [Abstract][Full Text] [Related]
48. Ciprofloxacin and probiotic Escherichia coli Nissle add-on treatment in active ulcerative colitis: a double-blind randomized placebo controlled clinical trial. Petersen AM; Mirsepasi H; Halkjær SI; Mortensen EM; Nordgaard-Lassen I; Krogfelt KA J Crohns Colitis; 2014 Nov; 8(11):1498-505. PubMed ID: 24972748 [TBL] [Abstract][Full Text] [Related]
49. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. D'Haens G; Ferrante M; Vermeire S; Baert F; Noman M; Moortgat L; Geens P; Iwens D; Aerden I; Van Assche G; Van Olmen G; Rutgeerts P Inflamm Bowel Dis; 2012 Dec; 18(12):2218-24. PubMed ID: 22344983 [TBL] [Abstract][Full Text] [Related]
50. A new rapid quantitative test for fecal calprotectin predicts endoscopic activity in ulcerative colitis. Lobatón T; Rodríguez-Moranta F; Lopez A; Sánchez E; Rodríguez-Alonso L; Guardiola J Inflamm Bowel Dis; 2013 Apr; 19(5):1034-42. PubMed ID: 23470502 [TBL] [Abstract][Full Text] [Related]
51. Predictive value of faecal calprotectin in ulcerative colitis - single centre experience. Grgić D; Golubić K; Brinar M; Krznarić Ž Ann Med; 2022 Dec; 54(1):1570-1577. PubMed ID: 35635011 [TBL] [Abstract][Full Text] [Related]
52. Noninvasive biomarkers as surrogate predictors of clinical and endoscopic remission after infliximab induction in patients with refractory ulcerative colitis. Hassan EA; Ramadan HK; Ismael AA; Mohamed KF; El-Attar MM; Alhelali I Saudi J Gastroenterol; 2017; 23(4):238-245. PubMed ID: 28721978 [TBL] [Abstract][Full Text] [Related]
53. Limitations of the determination of faecal calprotectin in patients with ulcerative colitis and inflammatory polyps. Bermejo F; Algaba A; Bonillo D; Jiménez L; Guardiola-Arévalo A; Pacheco M; Castaño Á; Guerra I Gastroenterol Hepatol; 2020 Feb; 43(2):73-78. PubMed ID: 31648810 [TBL] [Abstract][Full Text] [Related]
54. Prognostic Value of Fecal Calprotectin to Inform Treat-to-Target Monitoring in Ulcerative Colitis. Dulai PS; Feagan BG; Sands BE; Chen J; Lasch K; Lirio RA Clin Gastroenterol Hepatol; 2023 Feb; 21(2):456-466.e7. PubMed ID: 35934286 [TBL] [Abstract][Full Text] [Related]
55. Accuracy of Faecal Calprotectin and Neutrophil Gelatinase B-associated Lipocalin in Evaluating Subclinical Inflammation in UlceRaTIVE Colitis-the ACERTIVE study. Magro F; Lopes S; Coelho R; Cotter J; Dias de Castro F; Tavares de Sousa H; Salgado M; Andrade P; Vieira AI; Figueiredo P; Caldeira P; Sousa A; Duarte MA; Ávila F; Silva J; Moleiro J; Mendes S; Giestas S; Ministro P; Sousa P; Gonçalves R; Gonçalves B; Oliveira A; Chagas C; Torres J; Dias CC; Lopes J; Borralho P; Afonso J; Geboes K; Carneiro F; J Crohns Colitis; 2017 Apr; 11(4):435-444. PubMed ID: 27664275 [TBL] [Abstract][Full Text] [Related]